Unstable angina non ST elevation myocardial infarction anticoagulant therapy: Difference between revisions
Smitakohli (talk | contribs) No edit summary |
m (Jair Basantes de la Calle moved page Unstable angina / non ST elevation myocardial infarction anticoagulant therapy to Unstable angina non ST elevation myocardial infarction anticoagulant therapy) |
||
(45 intermediate revisions by 9 users not shown) | |||
Line 1: | Line 1: | ||
{ | __NOTOC__ | ||
{{ | {| class="infobox" style="float:right;" | ||
{{CMG}} | |- | ||
| [[File:Siren.gif|30px|link=Unstable angina/ NSTEMI resident survival guide]]|| <br> || <br> | |||
| [[Unstable angina/ NSTEMI resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |||
|} | |||
{{Unstable angina / NSTEMI}} | |||
{{CMG}}; '''Associate Editors-in-Chief:''' [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S.; Smita Kohli, M.D. | |||
==Overview== | |||
Anticoagulation, traditionally with [[unfractionated heparin]] (UFH), is a cornerstone of therapy for patients with unstable angina]]/[[NSTEMI. | |||
Some of the agents available in this category include [[unfractionated heparin]], [[low molecular weight heparin]], direct thrombin inhibitors (e.g., [[bivalirudin]]) factor Xa Inhibitors (e.g., [[fondaparinux]]), and [[warfarin]]. These agents are also sometimes referred to as [[antithrombin]]s, although, it should be noted that they often inhibit one or more proteins in the coagulation cascade before [[thrombin]]. | |||
==Anticoagulant Therapy in UA/NSTEMI== | |||
You can read in greater detail about each of the therapies specifically in relation to unstable angina and NSTEMI, by clicking on the link for that therapy: | |||
*[[Unstable angina / NSTEMI unfractionated heparin therapy |Unfractionated heparin]] | |||
*[[Unstable angina / NSTEMI low molecular weight heparin therapy |Low molecular weight heparin]] | |||
*[[Unstable angina / NSTEMI direct thrombin inhibitors therapy |Direct thrombin inhibitors]] | |||
*[[Unstable angina / NSTEMI factor Xa inhibitors therapy |Factor Xa inhibitors]] | |||
*[[Unstable angina / NSTEMI long term anticoagulation therapy |Long-term anticoagulation]]''' | |||
== | ==2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes (DO NOT EDIT) <ref name=Guidelines> Ezra A. Amsterdam, MD, FACC; Nanette K. Wenger, MD et al.2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC. September 2014 (ahead of print) </ref>== | ||
== | ===Initial Parenteral Anticoagulant Therapy in Patients With Definite NSTE-ACS=== | ||
= | {|class="wikitable" | ||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"| | |||
<nowiki>"</nowiki>'''1.'''In patients with NSTE-ACS, anticoagulation, in addition to antiplatelet therapy, is recommended for all patients irrespective of initial treatment strategy. Treatment options include: | |||
* [[Enoxaparin]]: 1 mg/kg subcutaneous (SC) every 12 hours (reduce dose to 1 mg/kg SC once daily in patients with [[creatinine]] clearance [CrCl] <30 mL/min), continued for the duration of hospitalization or until [[PCI]] is performed. An initial intravenous loading dose is 30 mg. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' | |||
* [[Bivalirudin]]: 0.10 mg/kg loading dose followed by 0.25 mg/kg per hour (only in patients managed with an early invasive strategy), continued until diagnostic [[angiography]] or [[PCI]], with only provisional use of GP IIb/IIIa inhibitor, provided the patient is also treated with DAPT. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | |||
[[ | |||
[[ | * [[Fondaparinux]]: 2.5 mg SC daily, continued for the duration of hospitalization or until [[PCI]] is performed. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | ||
[[ | * If [[PCI]] is performed while the patient is on [[fondaparinux]], an additional anticoagulant with anti-IIa activity (either UFH or bivalirudin) should be administered because of the risk of catheter thrombosis. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | ||
* [[UFH]] IV: initial loading dose of 60 IU/kg (maximum 4,000 IU) with initial infusion of 12 IU/kg per hour (maximum 1,000 IU/h) adjusted per activated partial thromboplastin time to maintain therapeutic anticoagulation according to the specific hospital protocol, continued for 48 hours or until PCI is performed. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowikI> | |||
[[ | |} | ||
===PCI—General Considerations=== | |||
====Anticoagulant Therapy in Patients Undergoing PCI==== | |||
== | {|class="wikitable" | ||
[[ | |- | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' An anticoagulant should be administered to patients with NSTE-ACS undergoing [[PCI]] to reduce the risk of intracoronary and catheter [[thrombus]] formation. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Intravenous [[UFH]] is useful in patients with NSTE-ACS undergoing [[PCI]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' [[Bivalirudin]] is useful as an anticoagulant with or without prior treatment with [[UFH]] in patients with NSTE-ACS undergoing [[PCI]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''4.''' An additional dose of 0.3 mg/kg IV enoxaparin should be administered at the time of [[PCI]] to patients with NSTE-ACS who have received fewer than 2 therapeutic subcutaneous doses (e.g., 1 mg/kg SC) or received the last subcutaneous [[enoxaparin]] dose 8 to 12 hours before [[PCI]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''5.''' If [[PCI]] is performed while the patient is on [[fondaparinux]], an additional 85 IU/kg of [[UFH]] should be given intravenously immediately before [[PCI]] because of the risk of catheter [[thrombosis]] (60 IU/kg IV if a GP IIb/IIIa inhibitor used with [[UFH]] dosing based on the target-activated clotting time). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''6.''' In patients with NSTE-ACS, anticoagulant therapy should be discontinued after [[PCI]] unless there is a compelling reason to continue such therapy. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit) | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' [[Fondaparinux]] should not be used as the sole anticoagulant to support [[PCI]] in patients with NSTEACS due to an increased risk of catheter [[thrombosis]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' In patients with NSTE-ACS undergoing [[PCI]] who are at high risk of bleeding, it is reasonable to use [[bivalirudin]] monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |||
==ACC | {|class="wikitable" | ||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Performance of [[PCI]] with [[enoxaparin]] may be reasonable in patients treated with upstream subcutaneous [[enoxaparin]] for NSTE-ACS. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |||
===Medical Regimen and Use of Medications at Discharge=== | |||
====Combined Oral Anticoagulant Therapy and Antiplatelet Therapy in Patients With NSTEACS==== | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' The duration of triple antithrombotic therapy with a [[vitamin K antagonist]], [[aspirin]], and a P2Y12 receptor inhibitor in patients with NSTE-ACS should be minimized to the extent possible to limit the risk of [[bleeding]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' [[Proton pump inhibitor]]s should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a [[vitamin K antagonist]], [[aspirin]], and a P2Y12 receptor inhibitor. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
===Class IIa= | {|class="wikitable" | ||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Proton pump inhibitor]] use is reasonable in patients with NSTE-ACS without a known history of [[gastrointestinal bleeding]] who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y12 receptor inhibitor. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Targeting oral anticoagulant therapy to a lower [[international normalized ratio]] (INR) (e.g., 2.0 to 2.5) may be reasonable in patients with NSTE-ACS managed with aspirin and a P2Y12 inhibitor. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
== | ==2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non -ST-Elevation Myocardial Infarction (DO NOT EDIT)<ref name="pmid21444888">{{cite journal| author=Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE et al.| title=2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2011 | volume= 123 | issue= 18 | pages= e426-579 | pmid=21444888 | doi=10.1161/CIR.0b013e318212bb8b | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21444888 }} </ref>== | ||
===Anticoagulant Therapy (DO NOT EDIT)<ref name="pmid21444888">{{cite journal| author=Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE et al.| title=2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2011 | volume= 123 | issue= 18 | pages= e426-579 | pmid=21444888 | doi=10.1161/CIR.0b013e318212bb8b | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21444888 }} </ref>=== | |||
== | {|class="wikitable" | ||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"| | |||
<nowiki>"</nowiki>'''1.''' Anticoagulant therapy should be added to antiplatelet therapy in [[UA]] / [[NSTEMI]] patients as soon as possible after presentation. | |||
|- | |||
| bgcolor="LightGreen"| | |||
'''a)''' For patients in whom an invasive strategy is selected, regimens with established efficacy at a ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' include [[enoxaparin]] and [[UFH]], and those with established efficacy at a ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' include [[bivalirudin]] and [[fondaparinux]]. | |||
|- | |||
| bgcolor="LightGreen"| | |||
'''b)''' For patients in whom a conservative strategy is selected, regimens using either [[enoxaparin]]<sup><nowiki>‡</nowiki></sup> or [[UFH]] ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' or [[fondaparinux]] ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' have established efficacy. See also Class IIa recommendation below. | |||
|- | |||
| bgcolor="LightGreen"| | |||
'''c)''' In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, [[fondaparinux]] is preferable. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |||
== | {|class="wikitable" | ||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
| bgcolor="LemonChiffon"| | |||
<nowiki>"</nowiki>'''1.''' For [[UA]] / [[NSTEMI]] patients in whom an initial conservative strategy is selected, [[enoxaparin]]<sup><nowiki>‡</nowiki></sup> or [[fondaparinux]] is preferable to [[UFH]] as [[anticoagulant therapy]], unless [[CABG]] is planned within 24 h. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |||
{{ | {{cquote| | ||
<sup><nowiki>‡</nowiki></sup> Limited data are available for the use of other LMWHs (e.g., dalteparin) in UA/NSTEMI.}} | |||
==References== | |||
{{Reflist|2}} | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Ischemic heart diseases]] | |||
[[Category:Intensive care medicine]] | |||
[[Category:Disease]] | |||
[[Category:Cardiology]] | |||
[[Category:Emergency medicine]] | |||
[[Category:Mature chapter]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Up-To-Date cardiology]] | |||
[[Category:Best pages]] |
Latest revision as of 21:13, 5 December 2022
Resident Survival Guide |
Unstable angina / NSTEMI Microchapters |
Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders |
Special Groups |
Diagnosis |
Laboratory Findings |
Treatment |
Antitplatelet Therapy |
Additional Management Considerations for Antiplatelet and Anticoagulant Therapy |
Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS |
Mechanical Reperfusion |
Discharge Care |
Case Studies |
Unstable angina non ST elevation myocardial infarction anticoagulant therapy On the Web |
FDA on Unstable angina non ST elevation myocardial infarction anticoagulant therapy |
CDC onUnstable angina non ST elevation myocardial infarction anticoagulant therapy |
Unstable angina non ST elevation myocardial infarction anticoagulant therapy in the news |
Blogs on Unstable angina non ST elevation myocardial infarction anticoagulant therapy |
to Hospitals Treating Unstable angina non ST elevation myocardial infarction anticoagulant therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.; Smita Kohli, M.D.
Overview
Anticoagulation, traditionally with unfractionated heparin (UFH), is a cornerstone of therapy for patients with unstable angina]]/[[NSTEMI. Some of the agents available in this category include unfractionated heparin, low molecular weight heparin, direct thrombin inhibitors (e.g., bivalirudin) factor Xa Inhibitors (e.g., fondaparinux), and warfarin. These agents are also sometimes referred to as antithrombins, although, it should be noted that they often inhibit one or more proteins in the coagulation cascade before thrombin.
Anticoagulant Therapy in UA/NSTEMI
You can read in greater detail about each of the therapies specifically in relation to unstable angina and NSTEMI, by clicking on the link for that therapy:
- Unfractionated heparin
- Low molecular weight heparin
- Direct thrombin inhibitors
- Factor Xa inhibitors
- Long-term anticoagulation
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes (DO NOT EDIT) [1]
Initial Parenteral Anticoagulant Therapy in Patients With Definite NSTE-ACS
Class I |
"1.In patients with NSTE-ACS, anticoagulation, in addition to antiplatelet therapy, is recommended for all patients irrespective of initial treatment strategy. Treatment options include:
|
PCI—General Considerations
Anticoagulant Therapy in Patients Undergoing PCI
Class I |
"1. An anticoagulant should be administered to patients with NSTE-ACS undergoing PCI to reduce the risk of intracoronary and catheter thrombus formation. (Level of Evidence: C)" |
"2. Intravenous UFH is useful in patients with NSTE-ACS undergoing PCI. (Level of Evidence: C)" |
"3. Bivalirudin is useful as an anticoagulant with or without prior treatment with UFH in patients with NSTE-ACS undergoing PCI. (Level of Evidence: B)" |
"4. An additional dose of 0.3 mg/kg IV enoxaparin should be administered at the time of PCI to patients with NSTE-ACS who have received fewer than 2 therapeutic subcutaneous doses (e.g., 1 mg/kg SC) or received the last subcutaneous enoxaparin dose 8 to 12 hours before PCI. (Level of Evidence: B)" |
"5. If PCI is performed while the patient is on fondaparinux, an additional 85 IU/kg of UFH should be given intravenously immediately before PCI because of the risk of catheter thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with UFH dosing based on the target-activated clotting time). (Level of Evidence: B)" |
"6. In patients with NSTE-ACS, anticoagulant therapy should be discontinued after PCI unless there is a compelling reason to continue such therapy. (Level of Evidence: C)" |
Class III (No Benefit) |
"1. Fondaparinux should not be used as the sole anticoagulant to support PCI in patients with NSTEACS due to an increased risk of catheter thrombosis. (Level of Evidence: B)" |
Class IIa |
"1. In patients with NSTE-ACS undergoing PCI who are at high risk of bleeding, it is reasonable to use bivalirudin monotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist. (Level of Evidence: B)" |
Class IIb |
"1. Performance of PCI with enoxaparin may be reasonable in patients treated with upstream subcutaneous enoxaparin for NSTE-ACS. (Level of Evidence: B)" |
Medical Regimen and Use of Medications at Discharge
Combined Oral Anticoagulant Therapy and Antiplatelet Therapy in Patients With NSTEACS
Class I |
"1. The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y12 receptor inhibitor in patients with NSTE-ACS should be minimized to the extent possible to limit the risk of bleeding. (Level of Evidence: C)" |
"2. Proton pump inhibitors should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y12 receptor inhibitor. (Level of Evidence: C)" |
Class IIa |
"1. Proton pump inhibitor use is reasonable in patients with NSTE-ACS without a known history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y12 receptor inhibitor. (Level of Evidence: C)" |
Class IIb |
"1. Targeting oral anticoagulant therapy to a lower international normalized ratio (INR) (e.g., 2.0 to 2.5) may be reasonable in patients with NSTE-ACS managed with aspirin and a P2Y12 inhibitor. (Level of Evidence: C)" |
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non -ST-Elevation Myocardial Infarction (DO NOT EDIT)[2]
Anticoagulant Therapy (DO NOT EDIT)[2]
Class I |
"1. Anticoagulant therapy should be added to antiplatelet therapy in UA / NSTEMI patients as soon as possible after presentation. |
a) For patients in whom an invasive strategy is selected, regimens with established efficacy at a (Level of Evidence: A) include enoxaparin and UFH, and those with established efficacy at a (Level of Evidence: B) include bivalirudin and fondaparinux. |
b) For patients in whom a conservative strategy is selected, regimens using either enoxaparin‡ or UFH (Level of Evidence: A) or fondaparinux (Level of Evidence: B) have established efficacy. See also Class IIa recommendation below. |
c) In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, fondaparinux is preferable. (Level of Evidence: B)" |
Class IIa |
"1. For UA / NSTEMI patients in whom an initial conservative strategy is selected, enoxaparin‡ or fondaparinux is preferable to UFH as anticoagulant therapy, unless CABG is planned within 24 h. (Level of Evidence: B)" |
“ |
‡ Limited data are available for the use of other LMWHs (e.g., dalteparin) in UA/NSTEMI. |
” |
References
- ↑ Ezra A. Amsterdam, MD, FACC; Nanette K. Wenger, MD et al.2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC. September 2014 (ahead of print)
- ↑ 2.0 2.1 Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE; et al. (2011). "2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. 123 (18): e426–579. doi:10.1161/CIR.0b013e318212bb8b. PMID 21444888.